Overview

Tolerability Study of Xerecept® in Pediatric Patients

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Celtic Pharma Development Services
Treatments:
Corticotropin-Releasing Hormone